Why so many companies are betting on PROTACs as a superior therapeutic modality
With PROTACs currently in the clinical and preclinical stages, they are making exciting progress towards successfully treating patients who have been waiting for effective therapies for certain types of cancer, neurodegenerative diseases, autoimmune diseases, and more. The targeted degradation of…